<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161497">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996151</url>
  </required_header>
  <id_info>
    <org_study_id>MTE11</org_study_id>
    <nct_id>NCT00996151</nct_id>
  </id_info>
  <brief_title>Testosterone MD-Lotion Residual Washing Study</brief_title>
  <acronym>MTE11</acronym>
  <official_title>A Healthy Volunteer, Single Dose Phase I Trial to Determine the Amount of Testerone MD-Lotion 2% Remaining on the Axilla After Washing.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acrux DDS Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acrux DDS Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the amount of Testosteron MD-Lotion 2% remaining on the axilla after
      a single dose application in healthy males who undergo a post dose washing procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The amount of Testerone MD-Lotion 2% remaining on the axilla after a single dose application in healthy males who undergo a post dose washing procedure.</measure>
    <time_frame>March 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety and tolerability of Testosterone MD-Lotion 2% following a single dose application. This will be performed by review of adverse events, EKG and assessment of laboratory parameters (haematology, biochemistry, urinalysis and hormone levels).</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hypergonadism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone MD-Lotion</intervention_name>
    <description>Single dose Testosterone MD-Lotion 2%</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects ≥18 and ≤ 70 years

        Exclusion Criteria:

          -  Disqualifying concurrent condition or allergy/sensitivity to Testosterone MD-Lotion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tina Soulis, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Acrux Pharma Pty Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QPharm Pty Ltd</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <lastchanged_date>February 28, 2010</lastchanged_date>
  <firstreceived_date>October 12, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Tina Soulis, Director, Clinical Development</name_title>
    <organization>Acrux Pharma Pty Ltd</organization>
  </responsible_party>
  <keyword>Hypergonadism</keyword>
  <keyword>Testosterone Transfer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
